Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
Public ClinicalTrials.gov record NCT02449031. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective Observational Study in Cystic Fibrosis Patients With Chronic Respiratory Pseudomonas Aeruginosa Infection Treated With TOBI® PODHALER® (Tobramycin Inhalation Powder) or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.
Study identification
- NCT ID
- NCT02449031
- Recruitment status
- Completed
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 409 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 6 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2015 (Actual)
- Primary completion
- Dec 31, 2021 (Actual)
- Completion
- Dec 31, 2021 (Actual)
- Last update posted
- Mar 22, 2022
2015 – 2021
United States locations
- U.S. sites
- 47
- U.S. states
- 32
- U.S. cities
- 46
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Anchorage | Alaska | 99508 | — |
| Novartis Investigative Site | Little Rock | Arkansas | 72202 | — |
| Novartis Investigative Site | Bellflower | California | 90706 | — |
| Novartis Investigative Site | Fullerton | California | 92831 | — |
| Novartis Investigative Site | Los Angeles | California | 90027 | — |
| Novartis Investigative Site | Madera | California | 93636 | — |
| Novartis Investigative Site | Hartford | Connecticut | 06102 | — |
| Novartis Investigative Site | New Haven | Connecticut | 06519 | — |
| Novartis Investigative Site | Stamford | Connecticut | 06902 | — |
| Novartis Investigative Site | Gainesville | Florida | 32610 | — |
| Novartis Investigative Site | Miami | Florida | 33136 | — |
| Novartis Investigative Site | Orlando | Florida | 32803 | — |
| Novartis Investigative Site | Tampa | Florida | 33606 | — |
| Novartis Investigative Site | Atlanta | Georgia | 30322 | — |
| Novartis Investigative Site | Boise | Idaho | 83712 | — |
| Novartis Investigative Site | Chicago | Illinois | 60611 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46202-5225 | — |
| Novartis Investigative Site | Iowa City | Iowa | 52242 | — |
| Novartis Investigative Site | New Orleans | Louisiana | 70112 | — |
| Novartis Investigative Site | Boston | Massachusetts | 02115 | — |
| Novartis Investigative Site | Detroit | Michigan | 97205 | — |
| Novartis Investigative Site | Grand Rapids | Michigan | 49503 | — |
| Novartis Investigative Site | Ypsilanti | Michigan | 48197 | — |
| Novartis Investigative Site | Jackson | Mississippi | 39216 | — |
| Novartis Investigative Site | Kansas City | Missouri | 64108 | — |
| Novartis Investigative Site | Billings | Montana | 59101 | — |
| Novartis Investigative Site | Omaha | Nebraska | 68198 | — |
| Novartis Investigative Site | Lebanon | New Hampshire | 03756 | — |
| Novartis Investigative Site | New Brunswick | New Jersey | 8901 | — |
| Novartis Investigative Site | New Hyde Park | New York | 11040 | — |
| Novartis Investigative Site | Winston-Salem | North Carolina | 27157 | — |
| Novartis Investigative Site | Akron | Ohio | 44308-1062 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73104 | — |
| Novartis Investigative Site | Hershey | Pennsylvania | 17033-085 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Novartis Investigative Site | Philadelphia | Pennsylvania | 19107 | — |
| Novartis Investigative Site | Charleston | South Carolina | 29425 | — |
| Novartis Investigative Site | Sioux Falls | South Dakota | 57104 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37232 | — |
| Novartis Investigative Site | Austin | Texas | 78723 | — |
| Novartis Investigative Site | Dallas | Texas | 75390 | — |
| Novartis Investigative Site | Tyler | Texas | 75708 | — |
| Novartis Investigative Site | Salt Lake City | Utah | 84132 | — |
| Novartis Investigative Site | Burlington | Vermont | 5405 | — |
| Novartis Investigative Site | Norfolk | Virginia | 23507 | — |
| Novartis Investigative Site | Richmond | Virginia | 23298 | — |
| Novartis Investigative Site | Spokane | Washington | 99204 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02449031, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 22, 2022 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02449031 live on ClinicalTrials.gov.